Bright Minds Biosciences Inc.

NasdaqCM:DRUG Stock Report

Market Cap: US$655.1m

Bright Minds Biosciences Dividends and Buybacks

Dividend criteria checks 0/6

Bright Minds Biosciences does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-32.5%

Buyback Yield

Total Shareholder Yield-32.5%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Seeking Alpha • Jan 07

Bright Minds Biosciences: Positive BREAKTHROUGH Study Data Warrants 'Strong Buy' Rating

Summary Bright Minds Biosciences remains a "Strong Buy" after positive phase 2 data for BMB-101 in drug-resistant epilepsies. DRUG's BMB-101 achieved -73.1% and -63.3% median seizure reductions in Absence Epilepsy and DEE cohorts, respectively. Multiple 2026 catalysts include additional phase 2 data, phase 3 trial initiation, and a phase 2 PWS study for BMB-101. Recent $100M financing and ATM program extend the runway, but further capital raises may be needed as clinical programs advance. Read the full article on Seeking Alpha
Seeking Alpha • Apr 16

Bright Minds Biosciences: A Buy With A Major Catalyst In Q2 2025

Summary We are initiating coverage of Bright Minds Biosciences with a Buy rating, as we believe the stock is undervalued. We see a key catalyst in the Phase 2 data readout for BMB-101, which is expected in Q2 2025. The company has a decent balance sheet, with roughly $40.3 million in cash. It may need to raise capital by mid-2026 or earlier as R&D expenses increase. A strategic partnership or acquisition could enhance value if the company's pipeline proves successful in clinic. Read the full article on Seeking Alpha
Seeking Alpha • Aug 18

Bright Minds says no material events fueled rally

After over 100% surge in its share price, Canadian biotech Bright Minds Biosciences (NASDAQ:DRUG) (OTCQB:BMBIF) announced Thursday that the company is unaware of any material events or undisclosed corporate actions that caused today’s rally. The company announced this in response to a request by the Investment Industry Regulatory Organization of Canada, which has sought its comments on its recent trading activity. DRUG, a pre-clinical biosciences company, added ~121% during regular trading on above-average volumes. About 119.5 company shares changed hands, compared to the 65-day average volume of ~58.3K. “The Company is not aware of any material, undisclosed corporate developments and has no material change in its business or affairs that has not been publicly disclosed that would account for the recent increase in volume or price,” Bright Minds (DRUG) said. DRUG shares have lost ~3.2% in post-market trading. Read Seeking Alpha’s “On the Move” section to monitor shares with the biggest moves.

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if DRUG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DRUG's dividend payments have been increasing.

Dividend Yield vs Market

Bright Minds Biosciences Dividend Yield vs Market
How does DRUG dividend yield compare to the market?
SegmentDividend Yield
Company (DRUG)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.1%
Industry Average (Biotechs)2.1%
Analyst forecast (DRUG) (up to 3 years)n/a

Notable Dividend: Unable to evaluate DRUG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DRUG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate DRUG's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as DRUG has not reported any payouts.

Discover strong dividend paying companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/09 06:37
End of Day Share Price 2026/09/09 00:00
Earnings2026/06/30
Annual Earnings2025/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bright Minds Biosciences Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBaird
Charles MooreBaird
Joel BeattyBaird